Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

László, Tamás and Pinczés, László and Bátai, Bence and Varga, Luca and Timár, Botond and Gulyás, Anita and Tárkányi, Ilona and Plander, Márk and Nagy, Zsolt and Rajnics, Péter and Egyed, Miklós and Molnár, Zsuzsa and Rottek, János and Masszi, András and Tamáska, Péter and Szász, Róbert and Illés, Árpád and Alpár, Donát and Magyari, Ferenc and Bödör, Csaba (2025) Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy. JOURNAL OF PATHOLOGY, 266. pp. 395-404. ISSN 0022-3417

Preview

Text Laszlo_et_al_J_Pathol_2025.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (4MB) | Preview

Abstract

In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments. Since patients relapsing on targeted treatment experience poor clinical outcomes, understanding the genetic foundation of resistance mechanisms in MCL is essential. In this study, we aimed to scrutinize the copy number profile and clonal dynamics of double-resistant MCL patients treated sequentially with Bruton’s tyrosine kinase inhibitor (BTKi) and venetoclax using low-coverage whole genome sequencing (lcWGS). Samples obtained after systemic therapy showed more copy number alterations (CNAs) (p = 0.039; Wilcoxon) compared to samples collected before treatment initiation. Patients showing early progression on BTKi demonstrated CNAs affecting cytobands encompassing the coding regions of NOTCH1, TRAF2, BIRC2, BIRC3, and ATM. A deletion in chromosome 9p21.3 was identified in two out of three venetoclax-resistant patients. For patient MCL2, progressing on ibrutinib but showing venetoclax resistance, a 9p21.3 deletion was found throughout the disease course, with acquired SMARCA4-del(19)(p13.3–q13.11) and DLC1–del(8)(p23.2–q11.1) observed at relapse, highlighting their role in disease progression and therapy resistance. Using lcWGS, an innovative genome-wide approach, this study revealed novel putative primary and acquired resistance mechanisms in BTKi and venetoclax double-resistant MCL patients.

Actions (login required)

Edit Item